Guidant Expects Similar 20% Penetration Of Expanded ICD Market Via MADIT
This article was originally published in The Gray Sheet
Executive Summary
Guidant projects the U.S. implantable defibrillator market will double to about $2.8 bil. as the applicable patient population expands based on indications evaluated in its recent MADIT II study. A related Guidant ICD PMA supplement was submitted in December 2001
You may also be interested in...
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations
Electrophysiological Data Needed To Determine ICD Benefit – NEJM Editorial
The cost-effectiveness of expanded indications for implantable cardioverter defibrillators may pose a barrier to reimbursement by CMS, a New England Journal of Medicine editorial suggests